Propanc Biopharma, Inc.: Form 10-Q for the period ended Mar 31, 2023
Filed with the SEC on May 15, 2023 and accepted by EDGAR at May 15, 2023, 16:11 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 3 months2023-01-01 to 2023-03-31 | $66.0k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2022-07-01 to 2023-03-31 | $242.2k | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2023-01-01 to 2023-03-31 | −$386.2k | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2022-07-01 to 2023-03-31 | −$1.6m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2023-01-01 to 2023-03-31 | $157.2k | us-gaap:InterestExpense |
| Interest expense | 9 months2022-07-01 to 2023-03-31 | $418.6k | us-gaap:InterestExpense |
| Income tax | 3 months2023-01-01 to 2023-03-31 | −$1.7k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2022-07-01 to 2023-03-31 | −$131.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2023-01-01 to 2023-03-31 | −$809.8k | us-gaap:NetIncomeLoss |
| Net income | 9 months2022-07-01 to 2023-03-31 | −$1.9m | us-gaap:NetIncomeLoss |
| Basic EPS | 3 months2023-01-01 to 2023-03-31 | $0.00 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2022-07-01 to 2023-03-31 | $0.00 | us-gaap:EarningsPerShareBasic |
| Operating cash flow | 9 months2022-07-01 to 2023-03-31 | −$927.3k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2023-03-31 | $93.2k | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2023-03-31 | $96.6k | us-gaap:AssetsCurrent |
| Total assets | At period end2023-03-31 | $143.7k | us-gaap:Assets |
| Current liabilities | At period end2023-03-31 | $3.1m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2023-03-31 | $3.1m | us-gaap:Liabilities |
| Long-term debt | At period end2023-03-31 | $519.7k | us-gaap:LongTermDebt |
| Shareholders' equity | At period end2023-03-31 | −$2.9m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001493152-23-017346. Last ingested by Listed: Oct 29, 2026, 17:01 ET. Listed shows no prices and gives no investment advice.